Filing Flows

Filing Flows › Companies › Agios Pharmaceuticals › Cash flow

Agios Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$60.4M in Q3 2026 · −$336M over twelve months

Operating cash flow−$59.2M
Capital spending−$1.2M
Free cash flow−$60.4M

Analysis

In Q3 2026, Agios Pharmaceuticals generated −$59.2M of operating cash flow and spent $1.2M on capital projects, leaving free cash flow of −$60.4M. That is $29.3M more than in Q3 2025 (−$89.7M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$332M; the largest uses were operating cash flow ($332M), capital spending ($4.3M); besides operations, cash came from other investing ($360M), shares issued ($12.0M); the cash balance rose by $35.8M.

Operating cash flow was −$59.2M against net income of −$65.0M. The largest differences: stock-based pay +$16.7M, inventory −$7.7M, receivables −$5.1M.

Free cash flow

Agios Pharmaceuticals: free cash flow by quarterAgios Pharmaceuticals: free cash flow by quarter−$134MQ4 2024−$112MQ1 2025−$78.0MQ2 2025−$89.7MQ3 2025−$97.3MQ4 2025−$120MQ1 2026−$58.5MQ2 2026−$60.4MQ3 2026
Operating cash flow less capital spending.
Agios Pharmaceuticals: operating cash flow against capital spendingAgios Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$133M$967KQ4 2024−$111M$766KQ1 2025−$77.1M$875KQ2 2025−$88.2M$1.6MQ3 2025−$96.2M$1.1MQ4 2025−$119M$769KQ1 2026−$57.3M$1.2MQ2 2026−$59.2M$1.2MQ3 2026
Latest (Q3 2026): Operating cash flow −$59.2M, Capital spending $1.2M.

Capital allocation, year by year

Agios Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearAgios Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingBuybacksFY2021: Operating cash flow −$407MFY2021: Net borrowing −$578KFY2021: Shares issued $37.3MFY2021: Capital spending −$5.7MFY2021: Buybacks −$802M$37.3MFY2021FY2022: Operating cash flow −$309MFY2022: Net borrowing −$331KFY2022: Shares issued $2.7MFY2022: Capital spending −$4.9M$2.7MFY2022FY2023: Operating cash flow −$296MFY2023: Shares issued $5.4MFY2023: Capital spending −$999K$5.4MFY2023FY2024: Operating cash flow −$390MFY2024: Shares issued $14.4MFY2024: Asset sales $200MFY2024: Capital spending −$1.7M$214MFY2024FY2025: Operating cash flow −$373MFY2025: Shares issued $8.7MFY2025: Capital spending −$4.3M$8.7MFY2025
Over these 5 years operating cash flow totalled −$1.8B; the largest uses were operating cash flow ($1.8B) and buybacks ($802M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$630M
Debtnone
Net cash$630M
Cash runway23 months

Agios Pharmaceuticals is burning cash: its operations consume cash, a free cash flow of −$336M a year at the current rate against $630M of cash and investments: a runway of about 23 months before any new financing.

Where the cash came from and went

Agios Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Agios Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Other investing$85.1MOperating cash flow−$59.2MCash drawn (+) / kept (−)−$28.9MShares issued$4.2MCapital spending−$1.2M
Agios Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Agios Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing$360MOperating cash flow−$332MCash drawn (+) / kept (−)−$35.8MShares issued$12.0MCapital spending−$4.3M

From profit to cash

Agios Pharmaceuticals: net income to operating cash flow, Q3 2026Agios Pharmaceuticals: net income to operating cash flow, Q3 2026Net income−$65.0MStock-based pay$16.7MReceivables−$5.1MInventory−$7.7MPayables$2.9MAccrued liabilities$3.4MContract assets−$3.5MPrepaid and other assets−$26KOperating cash flow−$59.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$59.2M−$1.2M$4.2M−$28.9M−$60.4M
Q2 2026−$57.3M−$1.2M$3.1M$14.0M−$58.5M
Q1 2026−$119M−$769K$2.1M−$24.5M−$120M
Q4 2025−$96.2M−$1.1M$2.6M$3.6M−$97.3M
Q3 2025−$88.2M−$1.6M$4.4M−$11.8M−$89.7M
Q2 2025−$77.1M−$875K$65K−$1.9M−$78.0M
Q1 2025−$111M−$766K$1.6M−$2.7M−$112M
Q4 2024−$133M−$967K$4.8M$177M−$134M

Agios Pharmaceuticals: income statement and cash flow

Agios Pharmaceuticals, Q3 2026: revenue $55.4M (+330% year over year), operating margin -139.3%. The chart follows the revenue to costs, profit and cash.

Agios Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.